Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Annovis Bio (ANVS)
NYSE:ANVS
Holding ANVS?
Track your performance easily
ANVS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.53 - $22.49
Previous Close$6.65
Volume318.70K
Average Volume (3M)229.32K
Market Cap
$98.58M
Enterprise Value$79.15M
Total Cash (Recent Filing)$12.60M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.49
Next Earnings
Apr 08, 2025EPS Estimate
-$0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.85
Shares Outstanding13,797,242
10 Day Avg. Volume222,753
30 Day Avg. Volume229,321
Standard Deviation0.39
R-Squared0.05
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)12.82
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.36
Forecast
1Y Price Target
$27.00Price Target Upside277.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Annovis Bio News
PremiumCompany Announcements
Annovis Bio Files Patents for Neurodegenerative Combination TherapiesBulls Say, Bears Say
Bulls Say
Innovative TherapiesRecent preclinical studies have shown that when buntanetap is combined with a GLP-1 agonist or PDE5 inhibitors, cognitive function in Alzheimer's mouse models improves to levels beyond those observed in healthy controls.
Market PotentialThe stock is viewed as significantly undervalued from a longer-term perspective, due to the high unmet need in Alzheimer's disease and the large potential market.
Regulatory ProgressThe FDA granted clearance to Annovis Bio to proceed with pivotal Phase 3 studies of its lead candidate buntanetap.
Bears Say
Financial PerformanceAnnovis filed its 10-Q reporting 2Q24 results with a net loss of ($5.0M) and ended the period with ~$4.0M in cash on the balance sheet.
Funding ChallengesThe company will need to secure additional funding to support the conduction of pivotal trials with its lead candidate, buntanetap.
Regulatory And Investment RisksThe company characterized the potential filing of a new drug application (NDA) in PD as 'aggressive,' suggesting an alternate path involving a new 18-month Phase 3 study.
---
Ownership Overview
24.77% Insiders
3.30% Mutual Funds
5.16% Other Institutional Investors
63.43% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ANVS FAQ
What was Annovis Bio’s price range in the past 12 months?
Annovis Bio lowest stock price was $4.53 and its highest was $22.49 in the past 12 months.
What is Annovis Bio’s market cap?
Currently, no data Available
When is Annovis Bio’s upcoming earnings report date?
Annovis Bio’s upcoming earnings report date is Apr 08, 2025 which is in 134 days.
How were Annovis Bio’s earnings last quarter?
Annovis Bio released its earnings results on Nov 11, 2024. The company reported -$0.97 earnings per share for the quarter, missing the consensus estimate of -$0.683 by -$0.287.
Is Annovis Bio overvalued?
According to Wall Street analysts Annovis Bio’s price is currently Undervalued.
Does Annovis Bio pay dividends?
Annovis Bio does not currently pay dividends.
What is Annovis Bio’s EPS estimate?
Annovis Bio’s EPS estimate is -$0.32.
How many shares outstanding does Annovis Bio have?
Annovis Bio has 13,797,242 shares outstanding.
What happened to Annovis Bio’s price movement after its last earnings report?
Annovis Bio reported an EPS of -$0.97 in its last earnings report, missing expectations of -$0.683. Following the earnings report the stock price went down -6.25%.
Which hedge fund is a major shareholder of Annovis Bio?
Currently, no hedge funds are holding shares in ANVS
---
Annovis Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.00 (277.89% Upside)
$27.00 (277.89% Upside)
Blogger Sentiment
Bullish
ANVS Sentiment 86%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.6%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.58%
12-Months-Change
Fundamentals
Return on Equity
-596.70%
Trailing 12-Months
Asset Growth
40.48%
Trailing 12-Months
Company Description
Annovis Bio
Annovis Bio Inc is a United States based clinical stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neuro degenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301.
---
ANVS Stock 12 Month Forecast
Average Price Target
$27.00
▲(277.89% Upside)
Technical Analysis
Bioxcel Therapeutics
―
Alzamend Neuro
―
Axsome Therapeutics
―
SELLAS Life Sciences Group
―
Best Analysts Covering ANVS
1 Year
1 Year Success Rate
3/16 ratings generated profit
1 Year Average Return
-25.68%
reiterated a buy rating 15 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 18.75% of your transactions generating a profit, with an average return of -25.68% per trade.
---